EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Vaccine adjuvants as potential cancer immunotherapeutics

Burcu Temizoz, Etsushi Kuroda, Ken J Ishii

International Immunology · 01.07.2016 · 28 (7) · 329-338

DOI: 10.1093/intimm/dxw015 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunology, online erschienen am 22.03.2016. Verfasst von Burcu Temizoz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Vaccine Science, WPI Immunology Frontier Research Center (iFReC), Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan Labora…. Die Arbeit wurde bisher 208-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accumulated evidence obtained from various clinical trials and animal studies suggested that cancer vaccines need better adjuvants than those that are currently licensed, which include the most commonly used alum and incomplete Freund’s adjuvant, because of either a lack of potent anti-tumor immunity or the induction of undesired immunity. Several clinical trials using immunostimulatory adjuvants, particularly agonistic as well as non-agonistic ligands for TLRs, C-type lectin receptors, retinoic acid-inducible gene I-like receptors and stimulator of interferon genes, have revealed their therapeutic potential not only as vaccine adjuvants but also as anti-tumor agents. Recently, combinations of such immunostimulatory or immunomodulatory adjuvants have shown superior efficacy over their singular use, suggesting that seeking optimal combinations of the currently available or well-characterized adjuvants may provide a better chance for the development of novel adjuvants for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, ImmunologicAlum CompoundsAnimalsCancer VaccinesClinical Trials as TopicHumansImmunomodulationImmunotherapyLectins, C-TypeNeoplasmsOligodeoxyribonucleotidesVaccination

Stichwörter der Autor:innen

CpG ODNSTINGTLRcombinationβ-glucan

Substanzen

Adjuvants, ImmunologicAlum CompoundsCPG-oligonucleotideCancer VaccinesLectins, C-TypeOligodeoxyribonucleotidesaluminum sulfate

Autor:innen und Institutionen

  • Laboratory of Vaccine Science, WPI Immunology Frontier Research Center (iFReC), Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan Laboratory of Adjuvant Innovation, National Institutes of Biomedical Innovat…

Zitieren

APA

Temizoz, B., Kuroda, E., & Ishii, K. J. (2016). Vaccine adjuvants as potential cancer immunotherapeutics. International Immunology, 28(7), 329-338. https://doi.org/10.1093/intimm/dxw015

Vancouver

Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. International Immunology. 2016;28(7):329-338. doi:10.1093/intimm/dxw015

BibTeX
@article{Temizoz2016,
  author = {Temizoz, Burcu and Kuroda, Etsushi and Ishii, Ken J},
  title = {Vaccine adjuvants as potential cancer immunotherapeutics},
  journal = {International Immunology},
  year = {2016},
  volume = {28},
  number = {7},
  pages = {329--338},
  doi = {10.1093/intimm/dxw015}
}
Kostenlos starten →